Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)

IInclusion Criteria -Adult patients (≥18 years old) seen in consultation or hospitalized in the Hepato-Gastroenterology Departments of the University Hospitals of Guadeloupe, French Guiana, and Réunion Island, with a diagnosis of MASLD. MASLD is defined as evidence of hepatic steatosis associated with overweight/obesity, type 2 diabetes, or metabolic syndrome according to ATP III (2005) criteria. - Patients affiliated with, or beneficiaries of, a social security scheme. - Free, informed, and written consent obtained from the participant and signed by both the participant and the investigator (no later than the day of inclusion and prior to any procedure required by the study). Who Should NOT Join This Trial: - Patients under 18 years of age. - Patients unable to provide willing to sign a consent form; so-called vulnerable populations (individuals under guardianship, judicial protection, etc.). - Presence of another cause of chronic liver disease, including: Viral hepatitis (B, C, or E) Primary biliary cholangitis or primary sclerosing cholangitis Autoimmune hepatitis Wilson's disease Hemochromatosis Alpha-1 antitrypsin deficiency Alcoholic liver disease, or daily alcohol consumption \>30 g/day for men or \>20 g/day for women -Pregnant women. Always talk to your doctor about whether this trial is right for you.